Open AccessFrom bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting
Author(s) -
M.G. Mumolo,
Lorenzo Bertani,
L. Ceccarelli,
G Laino,
G. Di Fluri,
Eleonora Cavalcante Albano,
G. Tapete,
Francesco Costa
Publication year - 2018
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v24.i33.3681
Subject(s) - calprotectin , medicine , irritable bowel syndrome , inflammatory bowel disease , context (archaeology) , pouchitis , gastroenterology , crohn's disease , disease , faecal calprotectin , paleontology , biology
Fecal calprotectin (FC) has emerged as one of the most useful tools for clinical management of inflammatory bowel diseases (IBD). Many different methods of assessment have been developed and different cut-offs have been suggested for different clinical settings. We carried out a comprehensive literature review of the most relevant FC-related topics: the role of FC in discriminating between IBD and irritable bowel syndrome (IBS) and its use in managing IBD patients In patients with intestinal symptoms, due to the high negative predictive value a normal FC level reliably rules out active IBD. In IBD patients a correlation with both mucosal healing and histology was found, and there is increasing evidence that FC assessment can be helpful in monitoring disease activity and response to therapy as well as in predicting relapse, post-operative recurrence or pouchitis. Recently, its use in the context of a treat-to-target approach led to a better outcome than clinically-based therapy adjustment in patients with early Crohn's disease. In conclusion, FC measurement represents a cheap, safe and reliable test, easy to perform and with a good reproducibility. The main concerns are still related to the choice of the optimal cut-off, both for differentiating IBD from IBS, and for the management of IBD patients.